Sareum develops small-molecule inhibitors targeting the JAK kinase family, including SDC-1801, which simultaneously blocks TYK2 and JAK1 for potential autoimmune disease treatment. A Phase 1a trial of SDC-1801 began dosing in Melbourne, Australia, in June 2023.
Triparna Sen,Carminia M. Della Corte,Snezana Milutinovic,Robert J. Cardnell,Lixia Diao,Kavya Ramkumar,Carl M. Gay,C. Allison Stewart,Youhong Fan,Li Shen,Ryan J. Hansen,Bryan Strouse,Michael P. Hedrick,Christian A. Hassig,John V. Heymach,Jing Wang et al.
Sareum is a clinical-stage small molecule company actively involved in developing next generation kinase inhibitors to treat autoimmune diseases and cancer.
The new Quoted Companies Alliance Corporate Governance Code (QCA Code) makes clear it is the prime responsibility of the Chairman to ensure the Company applies the QCA Code to best advantage of all stakeholders.
Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.
We are Sareum Holdings plc, a publicly listed company registered with number 05147578 and Sareum Limited, a limited company registered with number 04863659, together, “Sareum”.
Sareum (LSE: SAR) releases its annual financial results, following a warrant-backed funding round to advance its lead autoimmune drug toward mid-stage clinical trials. The company secures additional capital to support research and development efforts. The funding aims to accelerate progress in its pipeline, though trial outcomes remain pending.
Sareum has suspended trading on the AIM market to focus on raising equity capital. The company aims to secure additional funding through this strategic shift, potentially to support growth or operational initiatives.
Sareum (LSE: SAR) has halted trading to pursue a **Capital Access Window**, aiming to secure financing for its **lead clinical program**. The company awaits results from the proposed fundraise, which could support ongoing development efforts.
Sareum Holdings (LSE:SAR) sees a **27.59% stock price increase** following positive updates in its clinical trials. The company’s progress in research appears to be driving investor optimism and market momentum. Sareum specializes in developing treatments for neurological disorders, with its pipeline potentially advancing therapeutic options.
Sareum releases phase 1 clinical trial results for its autoimmune disease drug candidate, **93CH**. The data marks a key milestone in evaluating the safety and preliminary efficacy of the experimental treatment. The company’s progress follows ongoing efforts to develop therapies targeting autoimmune conditions.